127 related articles for article (PubMed ID: 31756535)
21. Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial.
Gooptu M; Kim HT; Chen YB; Rybka W; Artz A; Boyer M; Johnston L; McGuirk J; Shea TC; Jagasia M; Shaughnessy PJ; Reynolds CG; Fields M; Alyea EP; Ho VT; Glavin F; Dipersio JF; Westervelt P; Ritz J; Soiffer RJ
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2216-2223. PubMed ID: 30006305
[TBL] [Abstract][Full Text] [Related]
22. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
[TBL] [Abstract][Full Text] [Related]
23. Incidence, Risk Factors, and Outcomes of Chronic Graft-versus-Host Disease in Pediatric Patients with Hematologic Malignancies after T Cell-Replete Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation with Antithymocyte Globulin/Granulocyte Colony-Stimulating Factor.
Tang FF; Cheng YF; Xu LP; Zhang XH; Yan CH; Han W; Chen YH; Huang XJ; Wang Y
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1655-1662. PubMed ID: 32504861
[TBL] [Abstract][Full Text] [Related]
24. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
25. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
26. Risk factors for chronic graft-versus-host disease after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation in acute myeloid leukemia.
Lv M; Zhang X; Xu L; Wang Y; Yan C; Chen H; Chen Y; Han W; Wang F; Wang J; Liu K; Huang X; Mo X
Front Med; 2019 Dec; 13(6):667-679. PubMed ID: 31512033
[TBL] [Abstract][Full Text] [Related]
27. Meta-analysis of the actions of antithymocyte globulin in patients undergoing allogeneic hematopoietic cell transplantation.
Yuan J; Pei R; Su W; Cao J; Lu Y
Oncotarget; 2017 Feb; 8(7):10871-10882. PubMed ID: 28107198
[TBL] [Abstract][Full Text] [Related]
28. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant.
Ruggeri A; Sun Y; Labopin M; Bacigalupo A; Lorentino F; Arcese W; Santarone S; Gülbas Z; Blaise D; Messina G; Ghavamzadeh A; Malard F; Bruno B; Diez-Martin JL; Koc Y; Ciceri F; Mohty M; Nagler A
Haematologica; 2017 Feb; 102(2):401-410. PubMed ID: 27758821
[TBL] [Abstract][Full Text] [Related]
29. Personalizing rabbit anti-thymocyte globulin therapy for prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation: is there an optimal dose?
Shichijo T; Fuji S; Nagler A; Bazarbachi A; Mohty M; Savani BN
Bone Marrow Transplant; 2020 Mar; 55(3):505-522. PubMed ID: 31435032
[TBL] [Abstract][Full Text] [Related]
30. Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors.
Brissot E; Labopin M; Moiseev I; Cornelissen JJ; Meijer E; Van Gorkom G; Rovira M; Ciceri F; Griskevicius L; Blaise D; Forcade E; Mistrik M; Mielke S; Bulabois CE; Niittyvuopio R; Deconinck E; Ruggeri A; Sanz J; Spyridonidis A; Savani B; Giebel S; Nagler A; Mohty M
J Hematol Oncol; 2020 Jul; 13(1):87. PubMed ID: 32620146
[TBL] [Abstract][Full Text] [Related]
31. Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation.
Pasic I; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Mattsson J; Michelis FV
Ann Hematol; 2020 Jun; 99(6):1377-1387. PubMed ID: 32382774
[TBL] [Abstract][Full Text] [Related]
32. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group.
Basara N; Baurmann H; Kolbe K; Yaman A; Labopin M; Burchardt A; Huber C; Fauser AA; Schwerdtfeger R
Bone Marrow Transplant; 2005 May; 35(10):1011-8. PubMed ID: 15821768
[TBL] [Abstract][Full Text] [Related]
33. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
Finke J; Bethge WA; Schmoor C; Ottinger HD; Stelljes M; Zander AR; Volin L; Ruutu T; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Kolb HJ; Bertz H; Egger M; Grishina O; Socié G;
Lancet Oncol; 2009 Sep; 10(9):855-64. PubMed ID: 19695955
[TBL] [Abstract][Full Text] [Related]
34. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis.
Russell JA; Turner AR; Larratt L; Chaudhry A; Morris D; Brown C; Quinlan D; Stewart D
Biol Blood Marrow Transplant; 2007 Mar; 13(3):299-306. PubMed ID: 17317583
[TBL] [Abstract][Full Text] [Related]
35. Effects of two doses of anti-T lymphocyte globulin-Fresenius given after full-match sibling stem cell transplantation in acute myeloblastic leukemia patients who underwent myeloablative fludarabine/busulfan conditioning.
Boga C; Yeral M; Gereklioglu C; Asma S; Maytalman E; Aytan P; Kozanoglu I; Sariturk C; Ozdogu H
Hematol Oncol Stem Cell Ther; 2018 Sep; 11(3):149-157. PubMed ID: 29474820
[TBL] [Abstract][Full Text] [Related]
36. Lower dose anti-thymocyte globulin for GvHD prophylaxis results in improved survival after allogeneic stem cell transplantation.
Binkert L; Medinger M; Halter JP; Heim D; Gerull S; Holbro A; Lengerke C; Weisser M; Passweg JR
Bone Marrow Transplant; 2015 Oct; 50(10):1331-6. PubMed ID: 26121111
[TBL] [Abstract][Full Text] [Related]
37. Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI.
Nagler A; Labopin M; Dholaria B; Niittyvuopio R; Maertens J; Poiré X; Cornelissen J; Reményi P; Bourhis JH; Beguin Y; Malladi R; Kerre T; Schroyens W; Savani BN; Mohty M
Blood Adv; 2019 Jul; 3(13):1950-1960. PubMed ID: 31262738
[TBL] [Abstract][Full Text] [Related]
38. Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors.
Wakamatsu M; Terakura S; Ohashi K; Fukuda T; Ozawa Y; Kanamori H; Sawa M; Uchida N; Ota S; Matsushita A; Kanda Y; Nakamae H; Ichinohe T; Kato K; Murata M; Atsuta Y; Teshima T;
Blood Adv; 2019 Jan; 3(2):105-115. PubMed ID: 30626574
[TBL] [Abstract][Full Text] [Related]
39. Anti-thymocyte globulins for post-transplant graft-versus-host disease prophylaxis-A systematic review and meta-analysis.
Theurich S; Fischmann H; Chakupurakal G; Shimabukuro-Vornhagen A; Chemnitz JM; Holtick U; Rothe A; Scheid C; Hallek M; Skoetz N; von Bergwelt-Baildon M
Crit Rev Oncol Hematol; 2013 Oct; 88(1):178-86. PubMed ID: 23561334
[TBL] [Abstract][Full Text] [Related]
40. Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution.
Makanga DR; Guillaume T; Willem C; Legrand N; Gagne K; Cesbron A; Gendzekhadze K; Peterlin P; Garnier A; Le Bourgeois A; Béné MC; Chevallier P; Retière C
J Immunol; 2020 Sep; 205(5):1441-1448. PubMed ID: 32747504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
